Manufacturer
Macleods Pharmaceuticals Limited
Contents
Donepezil HCL
Indication
Mild to moderately severe dementia in Alzheimer's disease.
Instruction
May be taken with or without food.
Drug interaction
Increased risk of neuroleptic malignant syndrome w/ antipsychotics. Synergistic effect w/ succinylcholine, similar neuromuscular blocking agents, or cholinergic agonists (e.g. bethanechol). May interfere w/ the activity of anticholinergic medications. Increased plasma concentration when used w/ CYP3A4 inhibitors (e.g. ketoconazole, erythromycin) and CYP 2D6 inhibitors (e.g. fluoxetine, quinidine). Decreased plasma concentrations w/ enzyme inducers (e.g. rifampicin, phenytoin).
Malaysia
